Skip to content

Efficacy of Blade Needle Combined with Temporomandibular Joint Mobilization for Anterior Disc Displacement without Reduction (ADDWoR): A Randomized Controlled Trial Based on the Theory of Muscle and Bone Balance

Efficacy of Blade Needle Combined with Temporomandibular Joint Mobilization for Anterior Disc Displacement without Reduction (ADDWoR): A Randomized Controlled Trial Based on the Theory of Muscle and Bone Balance

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400093617
Enrollment
Unknown
Registered
2024-12-09
Start date
2024-12-25
Completion date
Unknown
Last updated
2026-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Temporomandibular disorders

Interventions

Blade and Needle Group:bladed needle therapy
Joint mobilization group:Joint mobilization
combined group:bladed needle therapy+Joint mobilization

Sponsors

Hangzhou Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) According to the DC /TMD diagnostic criteria, it was consistent with an irreducible anterior displacement of the articular disc in TMD, and the main symptoms were limited mouth opening (MMO = 2 points); (2) MRI showed an irreducible anterior displacement of the TMJ disc on the symptomatic side; (3) Patients aged 18-70 years old, without psychiatric disorders, coagulation disorders, hepatic or renal insufficiency, severe fracture sparing, and able to cooperate with treatment and examination; (4)Not receiving any TMD treatment (including pain medication, joint type manipulation, acupuncture treatment, etc.) within 3 months; (5) Patients voluntarily participate in this clinical trial, insist on completing the whole treatment process, and sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) A history of trauma or surgery to the temporomandibular joint; (2) Having temporomandibular tumor, osteoarticular tuberculosis, autoimmune osteoarticular system diseases; (3) Patients with serious underlying diseases (e.g., those with dysfunction of the heart, liver, spleen, lungs, kidneys, etc.), or serious life-threatening conditions; (4) Patients taking specific medications (e.g., anti-anxiety depressants or anti-psychotic drugs, non-steroidal anti-inflammatory drugs, muscarinic drugs, etc.); (5) Special populations (e.g. pregnant women, people with congenital coagulation disorders, people with extreme fear of needles and pain, etc.); (6) Other diseases and factors that cannot cooperate with the treatment.

Design outcomes

Primary

MeasureTime frame
Visual Analogue Scale, VAS;Maximum active Mouth Opening, MMO;

Secondary

MeasureTime frame
Pressure Pain Threshold, PPT;craniomandibular index, CMI;shear wavevelocity, SWV;

Countries

China

Contacts

Public ContactYuan Jianhui

Hangzhou Hospital of Traditional Chinese Medicine

819156579@qq.com+86 159 9006 2532

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 21, 2026